πŸ‡ΊπŸ‡Έ FDA
Patent

US 11191763

HIV post-exposure prophylaxis

granted A61KA61K31/4418A61K31/47

Quick answer

US patent 11191763 (HIV post-exposure prophylaxis) held by The United States of America, as represented by the Secretary, Department of Health and Human Services expires Mon Dec 02 2041 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
The United States of America, as represented by the Secretary, Department of Health and Human Services
Grant date
Tue Dec 07 2021 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon Dec 02 2041 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
28
CPC classes
A61K, A61K31/4418, A61K31/47, A61K31/513, A61K31/5377